139 related articles for article (PubMed ID: 19469001)
21. Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma.
Shankaraiah RC; Callegari E; Guerriero P; Rimessi A; Pinton P; Gramantieri L; Silini EM; Sabbioni S; Negrini M
Oncogene; 2019 Nov; 38(45):7035-7045. PubMed ID: 31409896
[TBL] [Abstract][Full Text] [Related]
22. Chronic Viral Hepatitis Signifies the Association of Premixed Insulin Analogues with Liver Cancer Risks: A Nationwide Population-Based Study.
Chiang CH; Kuo CS; Lin WW; Su JH; Chen JD; Huang KC
Int J Environ Res Public Health; 2019 Jun; 16(12):. PubMed ID: 31200528
[TBL] [Abstract][Full Text] [Related]
23. Incident Hepatocellular Carcinoma Risk in Patients Treated with a Sulfonylurea: A Nationwide, Nested, Case-Control Study.
Lee JY; Jang SY; Nam CM; Kang ES
Sci Rep; 2019 Jun; 9(1):8532. PubMed ID: 31189966
[TBL] [Abstract][Full Text] [Related]
24. Metformin Treatment Suppresses Melanoma Cell Growth and Motility Through Modulation of microRNA Expression.
Tseng HW; Li SC; Tsai KW
Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30754729
[TBL] [Abstract][Full Text] [Related]
25. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update.
Tateishi R; Uchino K; Fujiwara N; Takehara T; Okanoue T; Seike M; Yoshiji H; Yatsuhashi H; Shimizu M; Torimura T; Moriyama M; Sakaida I; Okada H; Chiba T; Chuma M; Nakao K; Isomoto H; Sasaki Y; Kaneko S; Masaki T; Chayama K; Koike K
J Gastroenterol; 2019 Apr; 54(4):367-376. PubMed ID: 30498904
[TBL] [Abstract][Full Text] [Related]
26. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Klein S; Dufour JF
Hepat Oncol; 2017 Jul; 4(3):83-98. PubMed ID: 30191057
[TBL] [Abstract][Full Text] [Related]
27. Diabetes Mellitus and Risk of Hepatocellular Carcinoma.
Li X; Wang X; Gao P
Biomed Res Int; 2017; 2017():5202684. PubMed ID: 29379799
[TBL] [Abstract][Full Text] [Related]
28. Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells.
Bhat M; Yanagiya A; Graber T; Razumilava N; Bronk S; Zammit D; Zhao Y; Zakaria C; Metrakos P; Pollak M; Sonenberg N; Gores G; Jaramillo M; Morita M; Alain T
Oncotarget; 2017 Aug; 8(31):50542-50556. PubMed ID: 28881582
[TBL] [Abstract][Full Text] [Related]
29. The role of thiazolidinediones in hepatocellular carcinoma risk reduction: a population-based cohort study in Taiwan.
Huang MY; Chung CH; Chang WK; Lin CS; Chen KW; Hsieh TY; Chien WC; Lin HH
Am J Cancer Res; 2017; 7(7):1606-1616. PubMed ID: 28744408
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients.
Ma S; Zheng Y; Xiao Y; Zhou P; Tan H
Medicine (Baltimore); 2017 May; 96(19):e6888. PubMed ID: 28489794
[TBL] [Abstract][Full Text] [Related]
31. Metformin exhibits the anti-proliferation and anti-invasion effects in hepatocellular carcinoma cells after insufficient radiofrequency ablation.
Zhang Q; Kong J; Dong S; Xu W; Sun W
Cancer Cell Int; 2017; 17():48. PubMed ID: 28450808
[TBL] [Abstract][Full Text] [Related]
32. Metformin promotes apoptosis in hepatocellular carcinoma through the CEBPD-induced autophagy pathway.
Tsai HH; Lai HY; Chen YC; Li CF; Huang HS; Liu HS; Tsai YS; Wang JM
Oncotarget; 2017 Feb; 8(8):13832-13845. PubMed ID: 28099155
[TBL] [Abstract][Full Text] [Related]
33. Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects.
Shang RZ; Qu SB; Wang DS
World J Gastroenterol; 2016 Dec; 22(45):9933-9943. PubMed ID: 28018100
[TBL] [Abstract][Full Text] [Related]
34. Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma.
Zhou YY; Zhu GQ; Liu T; Zheng JN; Cheng Z; Zou TT; Braddock M; Fu SW; Zheng MH
Sci Rep; 2016 Sep; 6():33743. PubMed ID: 27642100
[TBL] [Abstract][Full Text] [Related]
35. Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma.
Di Costanzo GG; Tortora R; Morisco F; Addario L; Guarino M; Cordone G; Falco L; Caporaso N
Target Oncol; 2017 Feb; 12(1):61-67. PubMed ID: 27503006
[TBL] [Abstract][Full Text] [Related]
36. Diabetes mellitus and metformin in hepatocellular carcinoma.
Fujita K; Iwama H; Miyoshi H; Tani J; Oura K; Tadokoro T; Sakamoto T; Nomura T; Morishita A; Yoneyama H; Masaki T
World J Gastroenterol; 2016 Jul; 22(27):6100-13. PubMed ID: 27468203
[TBL] [Abstract][Full Text] [Related]
37. Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs.
Papanagnou P; Stivarou T; Tsironi M
Pharmaceuticals (Basel); 2016 May; 9(2):. PubMed ID: 27164115
[TBL] [Abstract][Full Text] [Related]
38. Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature.
Ambe CM; Mahipal A; Fulp J; Chen L; Malafa MP
PLoS One; 2016; 11(3):e0151632. PubMed ID: 26967162
[TBL] [Abstract][Full Text] [Related]
39. Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis.
DePeralta DK; Wei L; Ghoshal S; Schmidt B; Lauwers GY; Lanuti M; Chung RT; Tanabe KK; Fuchs BC
Cancer; 2016 Apr; 122(8):1216-27. PubMed ID: 26914713
[TBL] [Abstract][Full Text] [Related]
40. Diabetes and Hepatitis C: A Two-Way Association.
Hammerstad SS; Grock SF; Lee HJ; Hasham A; Sundaram N; Tomer Y
Front Endocrinol (Lausanne); 2015; 6():134. PubMed ID: 26441826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
